WebAs a chemical biologist/neuroscientist and a surfer, I have always been drawn to the ocean and the way it makes me feel alive and free. But my love for the… Web13 dec. 2016 · He is a founder of Intellikine (acquired by Takeda) and Cellular Genomics (acquired by Gilead); co-founder of Araxes Pharmaceuticals, eFFECTOR Therapeutics and Mitokinin, LLC and a scientific advisor at Kura Oncology. Dr. Adams currently serves as president, research and development at Infinity Pharmaceuticals.
PharmaShots Incisive News in 3 Shots
Web10 mrt. 2024 · Biopharmaceutical giant AbbVie has agreed to acquire advanced therapeutics company Mitokinin. Jones Day is advising AbbVie on the transaction. The … Web2 mrt. 2024 · Mitokinin is a discovery-stage biotechnology company developing PINK1 targeted therapeutics for the treatment of neurodegenerative and mitochondrial diseases. Mitokinin's lead program targets idiopathic Parkinson's disease. Investors include Mission BioCapital, Pfizer Ventures, and Samambaia Investments. does hellman\u0027s mayo need to be refrigerated
Boston - BioLabs
WebMitokinin has advanced small molecule therapeutics that specifically increase the activity of active-form PINK1. Importantly, Mitokinin’s compounds do not interfere with the … WebMitokinin is taking a different approach to targeting kinases: we aim to increase the activity of active-form PINK1. A ‘LIGHT TOUCH’ MECHANISM: LEAVING PINK1’S … WebMontis Biosciences develops novel immuno-oncology therapeutics targeting the intersection between vascular dysfunction and immune suppression to treat solid tumors. Based on the work of Profs. Peter Carmeliet and Massimiliano Mazzone, Montis Biosciences has created a unique target screening and assay platform to discover novel targets … faa industry day 2022